Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Prothena Corporation plc today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Diabetes is a leading global health and economic challenge, affecting over 800 million people worldwide, with over 80% ...

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

2-Year U.S. Treasury Note Continuous Contract $103.313 0.008 0.01% 5-Year U.S. Treasury Note Continuous Contract $107.672 0.133 0.12% 10-Year U.S. Treasury Note Continuous Contract $110.063 0.234 ...

2-Year U.S. Treasury Note Continuous Contract $103.293-0.066-0.06% 5-Year U.S. Treasury Note Continuous Contract $107.469-0.258-0.24% 10-Year U.S. Treasury Note Continuous Contract $109.766-0.438 ...

The Trump administration released a 72-page report Thursday outlining its take on what's driving "a chronic disease crisis" ...